UNIGE document Scientific Article - Review
previous document  unige:150967  next document
add to browser collection

Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

Huinen, Zowi R
Huijbers, Elisabeth J M
van Beijnum, Judy R
Griffioen, Arjan W
Published in Nature reviews. Clinical oncology. 2021
Abstract Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities.
PMID: 33833434
Full text
Article (Published version) (2 MB) - document accessible for UNIGE members only Limited access to UNIGE
Research group Pharmacologie moléculaire
(ISO format)
HUINEN, Zowi R et al. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. In: Nature reviews. Clinical oncology, 2021. doi: 10.1038/s41571-021-00496-y https://archive-ouverte.unige.ch/unige:150967

144 hits



Deposited on : 2021-04-16

Export document
Format :
Citation style :